MAOA and depressive symptom measurement: The results suggest two compounds, xanthomicrol and salvigenin as potential natural starting molecules for developing novel selective MAO-A inhibitors, for prevention and treatment of psychiatric disorders such as depression and anxiety, and also cognitive impairments in Alzheimer’s and Parkinson’s Diseases.